DCC-3009
Phase 2Small molecule
DCC-3009 is one of 19 small molecule programs targeting Gastrointestinal Stromal Tumor. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal Stromal Tumor
#DrugCompanyPhaseTrials
1Gleevec
NovartisApproved
Sutent
PfizerApproved
Afinitor
NovartisApproved
Tasigna
AAzurity Pharmaceuticals
Approved
Piqray
NovartisApproved
Carnitor
LLeadiant Biosciences, Inc.
Approved
Novonorm
GGemini Therapeutics, Inc.
Approved
Opdivo
Bristol-Myers SquibbPhase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Nexavar
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCC-3009. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDeciphera Pharmaceuticals, LLC